Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients

Documenti analoghi

• Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel
  di: Audrey Couturier, et al.
  Pubblicazione: (2024)
• Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
  di: Anna Ossami Saidy, et al.
  Pubblicazione: (2025)
• Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee
  di: Nick van Sinderen, et al.
  Pubblicazione: (2025)
• Occult hepatitis B virus infection status is not associated with impaired efficacy of anti‐CD19 CAR‐T‐cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART‐SIE study
  di: Nicola Polverelli, et al.
  Pubblicazione: (2026)
• IntegrateALL: An end‐to‐end RNA‐seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B‐precursor ALL
  di: Nadine Wolgast, et al.
  Pubblicazione: (2026)